Opdivo nivolumab: Additional Phase II data

Additional data from the U.S. and French Phase II CheckMate -069 trial in 142 patients with previously untreated unresectable stage 3/4 melanoma showed that Opdivo plus Yervoy ipilimumab followed by Opdivo alone led

Read the full 336 word article

User Sign In